Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries

BMC Infectious Diseases

Research Article

Josefo Ferro¹  Charles H. King²  Sue C. Binder³  Carl H. Campbell³  Daniel G. Colley⁴  Susan Montgomery⁵  W. Evan Secor⁵  Pauline N. M. Mwinzi⁶  Diana M. S. Karanja⁶  Christopher C. Whalen⁷  Ye Shen⁷  Amara E. Ezeamama⁷  Chun-La He⁷  Stephen Rathbun⁷  Xiao-Ping Yin⁷  Safari Kinung’hi⁸  Amina Hamidou⁹  Amadou Garba⁹  Anna Phillips^1,10  Alan Fenwick^1,10  Jürg Utzinger^1,11  Eliézer K. N’Goran^1,12  Annette Olsen^1,13  Pascal Magnussen^1,13 

[1] Catholic University of Mozambique, Beira, Mozambique;Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA;Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA;Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA;Department of Microbiology, University of Georgia, Athens, GA, USA;Centers for Disease Control and Prevention, Atlanta, GA, USA;Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya;Department of Epidemiology & Biostatistics, University of Georgia, Athens, GA, USA;National Institute for Medical Research, Mwanza, Tanzania;Réseau International Schistosomoses, Environnement, Aménagement et Lutte (RISEAL-Niger), Niamey, Niger;Schistosomiasis Control Initiative, Imperial College, London, UK;Swiss Tropical and Public Health Institute, Basel, Switzerland;University of Basel, Basel, Switzerland;Unité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire;Centre Suisse de Recherches Scientifiques en Côte d’Ivoire, Abidjan, Côte d’Ivoire;University of Copenhagen, Copenhagen, Denmark;

关键词: Schistosomiasis;    Schistosoma haematobium;    Schistosoma mansoni;    Control;    Preventive chemotherapy;    Praziquantel;    Côte d’Ivoire;    Kenya;    Mozambique;    Niger;    Tanzania;   

DOI  :  10.1186/s12879-016-1575-2

 received in 2015-11-24, accepted in 2016-05-17,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was established in 2008 to answer strategic questions about schistosomiasis control. For programme managers, a high-priority question is: what are the most cost-effective strategies for delivering preventive chemotherapy (PCT) with praziquantel (PZQ)? This paper describes the process SCORE used to transform this question into a harmonized research protocol, the study design for answering this question, the village eligibility assessments and data resulting from the first year of the study.MethodsBeginning in 2009, SCORE held a series of meetings to specify empirical questions and design studies related to different schedules of PCT for schistosomiasis control in communities with high (gaining control studies) and moderate (sustaining control studies) prevalence of Schistosoma infection among school-aged children. Seven studies are currently being implemented in five African countries. During the first year, villages were screened for eligibility, and data were collected on prevalence and intensity of infection prior to randomisation and the implementation of different schemes of PZQ intervention strategies.ResultsThese studies of different treatment schedules with PZQ will provide the most comprehensive data thus far on the optimal frequency and continuity of PCT for schistosomiasis infection and morbidity control.ConclusionsWe expect that the study outcomes will provide data for decision-making for country programme managers and a rich resource of information to the schistosomiasis research community.Trial registrationThe trials are registered at International Standard Randomised Controlled Trial registry (identifiers: ISRCTN99401114, ISRCTN14849830, ISRCTN16755535, ISRCTN14117624, ISRCTN95819193 and ISRCTN32045736).

【 授权许可】

CC BY   
© The Author(s). 2016